CSL Ltd Annual Report 2020

Innovation across the value chain At CSL, innovation isn’t limited to the laboratory. We have fostered a culture of innovation that touches every part of our organisation and allows us to think and act progressively. Examples of our innovation abound, from the development of leading therapeutics to new ways to utilising the power of data science at our manufacturing sites around the world. Through our efforts we are able to better serve our patients, our employees and our communities. As part of the ongoing digital transformation that is a pillar of our 2030 strategy, we have implemented an organisation- wide effort to integrate data science, artificial intelligence (AI) andmachine learning throughout every aspect of the enterprise. In addition to using AI to solve many burdens that patients face, CSL is using AI to improve supply chain efficiency and comply with regulatory and legal requirements. The approach ensures each data science project is the right one to address individual team needs while benefitting CSL as a whole. It’s an effort that is only going to get bigger as we keep an eye firmly focused on the future. Bringing virtual reality to life in Bern CSL’s ongoing Digital Transformation is on display every day at our Bernmanufacturing site in Switzerland. Packaging employees are improving efficiency with the help of augmented reality. Workers wear specialised glasses and use barcode scanners to record and check incomingmaterials, ensuring that the valuable ingredients for lifesaving therapies are verified and logged. The Bern site also is improving training by making use of virtual reality technology. Aseptic filling trainees are taking courses in a virtual training space outside the production area. The setup ensures that normal operations continue while workers are being trained and at the same time reduces the risk of contamination in the sterile production area. Collaborating with patients to create digital tools By working closely with people living with sickle cell disease, our clinical teamdesigned an augmented reality app, which walks patients through the details of our CSL200 gene therapy clinical trial. Patients guided the design, including choosing the app’s avatar and selecting the voice patients hear in the immersive, augmented reality experience. This app is an innovative tool that will complement, not replace, existing tools for explaining clinical trials and gaining consent from patients. This use of technology has resulted in the exploration of similar applications for wider use across other clinical trials. Improving customer experience through technology Seqirus Medical Affairs launched three customised online tools that significantly improved efficiencies and effectiveness for our internal and external customers. – Amedical education grants tool enables healthcare professionals to submit applications easily and efficiently. – An investigator initiated research tool enabling academic researchers to submit applications for funding improves our review process andmanagement of ongoing projects. – An online publication tool improves the tracking of our scientific manuscript development and streamlines the review process of all our abstracts andmanuscripts. The tool manages the publication process from start to finish and provides an audit trail to maintain ethical, transparent publication practices. Inspecting with eagle eyes With our Bern site aiming to significantly boost production over the next several years, an innovative solution was needed to ensure all of the product could be inspected. Project Eagle answered the call. The project, which consisted of the implementation of fully automated inspection technology has boosted inspection rates from 35 vials per minute to 180 vials per minute, ensuringmanufacturing operations can keep up with future demand. CSL Limited Annual Report 2020 31